Genmab A/S (NASDAQ:GMAB) Receives Buy Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Genmab A/S (NASDAQ:GMAB) in a research note released on Tuesday morning, Benzinga reports. HC Wainwright currently has a $50.00 price target on the stock.

Several other equities research analysts also recently weighed in on GMAB. Truist Financial raised their price objective on Genmab A/S from $50.00 to $53.00 and gave the company a buy rating in a report on Tuesday, June 4th. BTIG Research raised their price objective on Genmab A/S from $46.00 to $47.00 and gave the company a buy rating in a report on Thursday, June 27th. Finally, Royal Bank of Canada raised Genmab A/S from a sector perform rating to an outperform rating in a report on Monday, July 15th. Three research analysts have rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of Hold and a consensus price target of $49.50.

Genmab A/S Stock Performance

Shares of GMAB opened at $27.34 on Tuesday. Genmab A/S has a 52-week low of $24.53 and a 52-week high of $39.53. The business’s fifty day moving average is $26.67 and its 200-day moving average is $28.16. The firm has a market cap of $18.08 billion, a price-to-earnings ratio of 22.78, a PEG ratio of 1.01 and a beta of 0.97.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Russell Investments Group Ltd. raised its position in shares of Genmab A/S by 137.7% in the 1st quarter. Russell Investments Group Ltd. now owns 939 shares of the company’s stock worth $28,000 after acquiring an additional 544 shares in the last quarter. GAMMA Investing LLC raised its position in shares of Genmab A/S by 194.0% in the 1st quarter. GAMMA Investing LLC now owns 1,135 shares of the company’s stock worth $34,000 after acquiring an additional 749 shares in the last quarter. Allspring Global Investments Holdings LLC bought a new position in shares of Genmab A/S in the 1st quarter worth about $43,000. Principal Securities Inc. bought a new position in shares of Genmab A/S in the 4th quarter worth about $77,000. Finally, Barometer Capital Management Inc. bought a new position in shares of Genmab A/S in the 4th quarter worth about $121,000. 7.07% of the stock is owned by institutional investors and hedge funds.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.